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Abstract – Toxoplasmosis is a worldwide health problem. Infection in pregnant women can result in severe fetal
morbidity or in subclinical neonatal infection; most subclinical cases develop ocular and neurological sequelae.
The purpose of this serological study was to assess the prevalence of Toxoplasma gondii in two populations of women
of childbearing age in Siena (Tuscany, Central Italy) and Bari (Apulia, Southern Italy) between 2013 and 2017 and in a
group of pregnant women in Bari in 2016–2017. Serum samples were tested for the presence of speciﬁc anti-
Toxoplasma gondii IgG antibodies by a commercially available ELISA test. The percentage of seropositive subjects
in Bari was signiﬁcantly higher than in Siena (22.4% vs. 12.4%) and an age-related trend was observed. A low
prevalence of T. gondii infection (13.8%) was observed among the pregnant women tested. In addition to showing
a signiﬁcant difference between Central and Southern Italy, this study provides updated data on T. gondii seropreva-
lence in women during childbearing age and pregnancy. The results conﬁrm a trend toward a decrease, especially in
younger people and pregnant women.
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Re´sume´ – Toxoplasma gondii chez les femmes en âge de procréer et pendant la grossesse : étude de la
séroprévalence dans le centre et le sud de l’Italie de 2013 à 2017. La toxoplasmose est un problème de santé
mondial. L’infection d’une femme enceinte peut entraîner une morbidité fœtale grave ou une infection néonatale
subclinique, et la plupart des cas subcliniques développeront des séquelles oculaires et neurologiques. Le but de
cette étude sérologique était d’évaluer la prévalence de Toxoplasma gondii dans deux populations de femmes en
âge de procréer à Sienne (Toscane, Italie centrale) et Bari (Pouilles, Italie du Sud) entre 2013 et 2017 et dans un
groupe de femmes enceintes à Bari en 2016-2017. Des échantillons de sérum ont été testés pour la présence
d’anticorps IgG anti-Toxoplasma gondii spéciﬁques par un test ELISA commercial. Le pourcentage de sujets
séropositifs à Bari était signiﬁcativement plus élevé qu’à Sienne (22,4 % vs 12,4 %) et une tendance liée à l’âge a
été observée. Une faible prévalence de l’infection à T. gondii (13,8 %) a été observée chez les femmes enceintes
testées. En plus de montrer une différence signiﬁcative entre le centre et le sud de l’Italie, cette étude fournit des
données actualisées sur la séroprévalence de T. gondii chez les femmes en âge de procréer et pendant la grossesse.
Les résultats conﬁrment une tendance à la baisse, notamment chez les jeunes et les femmes enceintes.
Introduction
Toxoplasma gondii (T. gondii) is a protozoan parasite of
worldwide distribution and one of the most common human
zoonoses, infecting more than a third of the world’s population
[17]. The parasite is horizontally transmitted to humans, mostly
by ingestion or handling of water, food or soil contaminated
with oocysts or raw or undercooked meat containing cysts.
Infection is asymptomatic or associated with ﬂu-like symptoms
in more than 80% of immunocompetent individuals [25]. If
primary infection occurs during pregnancy, T. gondii can cross
the placenta and may be vertically transmitted to the fetus
(congenital toxoplasmosis). Congenital toxoplasmosis may
cause abortion, stillbirth or result in major ocular and neurolog-
ical sequelae, ranging from slightly diminished vision to more
severe disorders, such as retinochoroiditis, hydrocephalus, and
intracerebral calciﬁcations [15]. The risk of congenital infection
and the severity of fetal damage depend on the gestational age
when maternal infection occurs [25]. The overall risk of con-
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pregnancy ranges from 20% to 50% if untreated [10].
Congenital toxoplasmosis can be prevented by identifying
non-immune women at the beginning of pregnancy, by provid-
ing information on how to avoid the infection, and by serolog-
ical follow-up. Serological follow-up is based on repeated
testing for speciﬁc IgG and IgM in order to distinguish, in
the case of positivity, between acute and chronic infections
[25]. In Italy, serological tests for toxoplasmosis are performed
routinely during pregnancy, with the ﬁrst evaluation carried out
by the 13th week of pregnancy, followed by monthly testing of
women who are seronegative for toxoplasmosis (total 5–7 tests)
[16, 22].
Toxoplasma gondii seroprevalence rates increase with age;
however, the rate of infection varies widely between countries
and regions according to dietary habits, health standards and
socioeconomic level. Improvements in hygiene conditions and
farming systems, together with increased socioeconomic levels,
have led to a declining seroprevalence in most industrialized
countries [25]. As toxoplasmosis causes serious illness when
it is vertically transmitted to the fetus during pregnancy, it has
a signiﬁcant impact on public health [12]. In Europe, nationwide
epidemiological surveillance for congenital toxoplasmosis is
currently implemented only in France and Germany. In Italy,
the surveillance system for congenital toxoplasmosis, reporting
data on live newborns from mothers with gestational toxoplas-
mosis, is active on a regional basis (e.g. Campania region)
[27]. However, a nationwide epidemiological surveillance
system for congenital toxoplasmosis is still lacking [1].
Consequently, no accurate estimates of the impact of toxoplas-
mosis on the population are available, and epidemiological
information on the prevalence of T. gondii infection is incom-
plete, area-based, and mostly focused on pregnant women
[3–5, 7, 8, 23, 24, 26, 28, 30]. Epidemiological data on T. gondii
seroprevalence in women of childbearing age are even more
scant [6, 11, 18, 20].
The aim of this study was to investigate the prevalence of
T. gondii IgG antibodies in women of childbearing age in
Tuscany (Central Italy) and Apulia (Southern Italy), and preg-
nant women in Apulia, in order to provide data on the current
state of toxoplasmosis in Italy.
Materials and methods
This study was performed on human serum samples
collected from women of childbearing age (15–45 years old):
409 serum samples were collected in the province of Siena
(Tuscany, Central Italy) in the years 2013, 2014, and 2016,
and 398 in the province of Bari (Apulia, Southern Italy) from
2015 to 2016. In addition, 232 samples were collected from
pregnant women in the province of Bari from 2016 to 2017.
Serum samples were anonymously collected in compliance
with Italian ethics law, and stored at the internal serum bank
of the Laboratory of Molecular Epidemiology, Department of
Molecular and Developmental Medicine, University of Siena.
A total of 1039 samples were tested for the presence of IgG
antibodies against T. gondii by “Enzywell Toxoplasma
IgG” (DIESSE-Siena, Italy) commercial ELISA kits, in accor-
dance with the manufacturer’s instructions. According to the
manufacturer, the test offers 100% sensitivity and speciﬁcity;
moreover, the presence of IgG antibodies against viruses such
as Cytomegalovirus, Rubella, Epstein Barr, Herpes Simplex,
and Mumps has no inﬂuence on the result of the test. On the
basis of the test criteria, samples were classiﬁed as negative if
the ratio between the optical density value of the sample and
that of the cut-off was <0.7; positive if this ratio was >1.3. Sam-
ples with borderline results (ratio 0.7 or 1.3) were retested
and, if still borderline when retested, excluded from the statis-
tical analysis.
Samples were stratiﬁed by age groups (15–25, 26–35, and
36–45 years old) and prevalence rates were calculated along
with their corresponding 95% conﬁdence intervals (CI).
Statistical analysis was performed by use of Yates’ corrected
chi-square test and chi-square test for trends to compare preva-
lence rates among different groups and areas. Statistical signif-
icance was set at p < 0.05, two-tailed.
Results
Of the 1039 serum samples tested, 19 had borderline results
when retested, and were therefore excluded from the statistical
analysis.
The overall anti-T. gondii IgG prevalence in samples
collected from women of childbearing age in the province of
Siena was 12.4% (9.5–16.0, CI), while in those collected in
the province of Bari was 22.4% (18.6–26.8, CI) (p < 0.001)
(Table 1). Signiﬁcant differences were also found when com-
paring age groups. The prevalence in the 15–25-years-old age
group was 4.2% (1.0–12.2, CI) in samples from Siena and
18.8% (12.1–27.8, CI) in samples from Bari (p < 0.01); in
the 26–35-years-old age group, prevalence was 9.4% (5.4–
15.5, CI) in Siena and 18.3% (13.2–24.9, CI) in Bari
(p = 0.04); ﬁnally, the prevalence in the 36–45-years-old age
group was 17.6% (12.8–25.8, CI) and 30.7% (23.3–39.2, CI)
in Siena and Bari, respectively (p < 0.01). An increasing preva-
lence among age groups was found both in samples from Siena
(p = 0.001) and Bari (p = 0.02).
The prevalence rate in samples collected from pregnant
women was 13.8% (9.8–18.9, CI) (Table 2). No signiﬁcant dif-
ferences were found between age groups, while differences
between pregnant women and women of childbearing age from
Bari were found to be signiﬁcant (p = 0.01), especially for the
36–45-years-old age group (p = 0.03).
Discussion
In this study, the prevalence of anti-T. gondii antibodies in
women of childbearing age from both the Tuscany and Apulia
regions is consistent with the declining trend observed in recent
decades in other regions in Italy [18, 20], as well as in other
European countries [2, 9, 13] and the United States [14]. In
Italy, T. gondii prevalence in women of childbearing age was
41.1% in the late 1980’s [6], and a trend toward a decrease
has become evident since 2001 [20]. This decline in prevalence
is correlated to declining incidence, due to lower exposure to
the parasite by changes in nutritional habits and by improved
hygiene practices in meat production [19].
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The introduction of modern farming systems and the
increase in consumption of frozen meat as the main factors
for T. gondii incidence reduction are particularly evident in
young people [13]. In fact, in this study, prevalence among
age groups shows an age-related increase, with lower rates in
younger women especially in samples collected in Siena.
As samples of this study were collected in two distinct
geographic areas of Italy, differences in prevalence between
Bari and Siena could be associated with sociodemographic
and cultural factors [20], including different nutritional habits.
Prevalence in pregnant women is also consistent with this
trend toward a decrease observed in Italy. Epidemiological
studies conducted on T. gondii seroprevalence in pregnant
women between the 1980’s and 1990’s revealed rates ranging
from 40.4% in Naples to 48.7% in the area of Parma [3, 4,
30], whereas more recent studies have found rates of T. gondii
prevalence in pregnant women between 21.5% and 27.5% [5, 7,
8, 26]. Pregnant women in this study showed a further decrease,
with an overall prevalence of 13.8%. As for women of child-
bearing age, this decrease could be associated with improve-
ments in quality of life and eating habits; however,
prevalence in pregnant women was found to be signiﬁcantly
lower. This difference could be explained by the fact that
pregnant women might be more aware of the speciﬁc hygiene
and dietary recommendations to prevent primary T. gondii
infection. In fact, the adoption of preventive measures due to
a greater awareness of the risk associated with toxoplasmosis
during gestation was already considered an explanation of
lower T. gondii prevalence in women than in men [21], and
it could be hypothesized that this kind of awareness is higher
after counseling and education programs in antenatal clinics.
In Italy, all pregnant women are strongly advised to undergo
free-of-charge serological testing for toxoplasmosis. This test-
ing is among the most important tools used to identify at-risk
women and is considered a cost-effective means of prevention.
For this reason, the diagnostic procedure is entirely covered by
the public healthcare system [29].
This study is limited by a small sample size, in particular for
samples from pregnant women, that were collected only in one
geographical setting. However, it provides updated data on
T. gondii seroprevalence in women of childbearing age and
during pregnancy in two different regions of Italy, conﬁrming
a decreasing trend in the incidence of the infection.
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